Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

Authors
Publication date
1 January 2018
Publisher
'Ovid Technologies (Wolters Kluwer Health)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Queensland eSpace

    redirect
    oaioai:espace.library.uq.edu.au:U...
    Last time updated on 28/03/2019